JP6262225B2 - オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 - Google Patents

オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 Download PDF

Info

Publication number
JP6262225B2
JP6262225B2 JP2015520594A JP2015520594A JP6262225B2 JP 6262225 B2 JP6262225 B2 JP 6262225B2 JP 2015520594 A JP2015520594 A JP 2015520594A JP 2015520594 A JP2015520594 A JP 2015520594A JP 6262225 B2 JP6262225 B2 JP 6262225B2
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
alkynyl
substituted
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015520594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522032A5 (enExample
JP2015522032A (ja
Inventor
コヴァック、ジョン・エス
Original Assignee
リクスト・バイオテクノロジー，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リクスト・バイオテクノロジー，インコーポレイテッド filed Critical リクスト・バイオテクノロジー，インコーポレイテッド
Publication of JP2015522032A publication Critical patent/JP2015522032A/ja
Publication of JP2015522032A5 publication Critical patent/JP2015522032A5/ja
Application granted granted Critical
Publication of JP6262225B2 publication Critical patent/JP6262225B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015520594A 2012-06-29 2013-06-28 オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 Expired - Fee Related JP6262225B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261666535P 2012-06-29 2012-06-29
US61/666,535 2012-06-29
US201361782894P 2013-03-14 2013-03-14
US61/782,894 2013-03-14
PCT/US2013/048697 WO2014005080A1 (en) 2012-06-29 2013-06-28 Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017206285A Division JP2018048178A (ja) 2012-06-29 2017-10-25 オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類

Publications (3)

Publication Number Publication Date
JP2015522032A JP2015522032A (ja) 2015-08-03
JP2015522032A5 JP2015522032A5 (enExample) 2016-08-18
JP6262225B2 true JP6262225B2 (ja) 2018-01-17

Family

ID=49783920

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015520594A Expired - Fee Related JP6262225B2 (ja) 2012-06-29 2013-06-28 オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
JP2017206285A Pending JP2018048178A (ja) 2012-06-29 2017-10-25 オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017206285A Pending JP2018048178A (ja) 2012-06-29 2017-10-25 オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類

Country Status (6)

Country Link
US (1) US20150174123A1 (enExample)
EP (1) EP2870161B1 (enExample)
JP (2) JP6262225B2 (enExample)
CN (1) CN104619710B (enExample)
CA (1) CA2876703A1 (enExample)
WO (1) WO2014005080A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US10149847B2 (en) 2012-06-29 2018-12-11 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
MX2015014249A (es) * 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
BR112016025659B1 (pt) 2014-05-13 2023-03-07 Novartis Ag Indutores de condrogênese, seu uso, e composição farmacêutica
US20170209434A1 (en) 2014-07-24 2017-07-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
CA2960989A1 (en) * 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
AU2016219853B2 (en) 2015-02-19 2019-05-16 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
HUE050177T2 (hu) * 2015-05-15 2020-11-30 Lixte Biotechnology Inc Oxabicikloheptán elõvegyületek
CA3046515A1 (en) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
US12440479B2 (en) 2018-03-28 2025-10-14 Georg-August-Universitaet Goettingen, Stiftung Oeffentlichen Rechts, Universitaetsmedizin Prevention or treatment of chronic organ injury
CN118791500B (zh) * 2024-06-17 2025-11-21 中国药科大学 7-氧杂双环[2.2.1]庚烷-2,3-二羧酸类衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931460A (en) * 1987-09-17 1990-06-05 E. R. Squibb & Sons, Inc. Post-ischemic myocardial dysfunction using thromboxane A2 antagonists
WO1998014606A1 (en) * 1996-10-04 1998-04-09 South Alabama Medical Science Foundation Method for diminishing myocardial infarction using protein phosphatase inhibitors
MX2009008347A (es) 2007-02-06 2009-10-19 Lixte Biotechnology Holdings I Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
US8058268B2 (en) 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
EP2309853A4 (en) * 2008-08-01 2012-04-25 Lixte Biotechnology Inc METHOD FOR CELL MITITULATING BY INHIBITION OF SERIN / THREONINE PHOSPHATASE
MX2015014249A (es) * 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
CA2960989A1 (en) * 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor

Also Published As

Publication number Publication date
CA2876703A1 (en) 2014-01-03
EP2870161B1 (en) 2018-08-08
JP2018048178A (ja) 2018-03-29
HK1209424A1 (en) 2016-04-01
WO2014005080A1 (en) 2014-01-03
US20150174123A1 (en) 2015-06-25
JP2015522032A (ja) 2015-08-03
CN104619710B (zh) 2017-09-22
CN104619710A (zh) 2015-05-13
EP2870161A4 (en) 2015-12-23
EP2870161A1 (en) 2015-05-13

Similar Documents

Publication Publication Date Title
JP6262225B2 (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
US10668062B2 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
EP4245752A2 (en) Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
TWI712409B (zh) 具有增進之治療指數的硝醯基予體
JP2003535034A (ja) ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
JP2009533457A (ja) Ｃ−ニトロソから誘導されるニトロキシル供与体
US10016397B2 (en) Selective AT2 receptor agonists for use in treatment of cachexia
JP2005501060A (ja) 硫黄含有有機硝酸化合物の使用法
EP3906969A1 (en) Antihypertensive polyol compound and derivative thereof
WO2023134732A9 (en) Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids
AU2013206215C9 (en) Positively charged water-soluble prodrugs of aspirin
US20120302575A1 (en) Methods for Preventing Oxidative Stress Injury of a Tissue by a Folate-Tempol Conjugate.
CN112209834B (zh) 一种有机亚硝酸根供体及其制备方法与医药用途
JP6648108B2 (ja) 生物学的シグナル伝達を改変するためのイミダゾール及びチアゾール組成物
HK1209424B (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
HK40091513A (en) Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
KR101456212B1 (ko) ｐ21의 발현을 증가시키는 활성을 갖는 화합물5,4'-디메톡시플라본의 항암제로서의 용도
WO2016189881A1 (en) Pharmaceutical composition for treating cerebral infarction
AU2002349876A1 (en) Methods of use for novel sulfur containing organic nitrate compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171025

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171213

R150 Certificate of patent or registration of utility model

Ref document number: 6262225

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees